IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies

INconnect28 - 29 September 2017, Berlin, Germany.
Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. Cloud computing solutions has reshaped promotional strategies of various Life Science companies and transformed modes of interactions with physicians.

As Life Science sector is currently improving and accelerating its correlation with IT, the Life Sciences Cloud Coalition have moved to the cloud computing and working with their patient through it.

Global Cloud Computing in Life Science Market is expected to expand at a rapid pace during the period of 2015 - 2023 due to the increasing use of cloud computing in Life Science research and development.

This event will serve as a business networking platform as well as a scientific examination of the advantages and disadvantages in implementing IT modernization and cloud computing.

Key Topics

  • Examination of the EU General Data Protection Regulation and practical implementation
  • Analysis of Data security and Privacy Global Outlook
  • Benchmark your IT approach to transformation
  • Understanding the need for Scalability and Flexibility of Cloud Computing
  • IT Infrastructure Modernisation in Pharma and Rea
  • World Implementations
  • Factors driving Digital and Mobile Technologies in Patient Engagement
  • Cloudy 2020: Cloudy Opportunities and Challenges in the future
  • Harmonization of data privacy laws across Europe
  • Discussion of pros and cons of private cloud and public cloud
  • e-commerce trends and application in Cloud

Target Audience

  • Pharmaceutical companies
  • Cloud Content Solution/Software Providers
  • Biotechnology companies
  • Medical Technology companies
  • Research Centers
  • Physicians

For further information, please visit:
http://www.inconnect.net/events/events/it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies

About INconnect
Academic management research shows that knowledge is a crucial asset for companies concerning sustained competitive advantage. Markets provide opportunities for companies to succeed in organizing themselves around new information on industry trends and technology. Those are the companies that can and will innovate.

Improved technologies and strategies are required for innovation. The only possible fuel for innovation are ideas. Ideas arise when the right people, get the right information, in the right context.

INconnect uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...